Rosuvastatin in patients with moderate brain trauma

Investigating the effectiveness of Rosuvastatin in patients with moderate brain trauma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230627058603N2

Enrollment

200

Registered

2024-01-04

Start date

2023-12-22

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate traumatic brain injury. Diffuse traumatic brain injury

Interventions

Intervention 1: Intervention group: Rosuvastatin with a dose of 20 mg (which is equivalent to 40 mg of Atorvastatin and 80 mg of Simvastatin) (21, 20) will be prescribed to patients daily for ten days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with a level of consciousness between 8-12 Informed consent of first-degree companions to enter the study

Exclusion criteria

Exclusion criteria: History of any brain disorders Normal Liver function tests

Design outcomes

Primary

Measure	Time frame
Improve the state of Glasgow Coma Scale (GCS). Timepoint: One, three and 6 months after the injury. Method of measurement: Glasgow coma scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Shafiei

Esfahan University of Medical Sciences

mui@mui.ac.ir+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026